Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics.

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise.

We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

Biotechnology

Gubra

Henrik Blou

Jacob Tórsheim Voltelen

Niels Vrang

Trine Nygaard Hamann

Kristoffer Rigbolt

Kristian Borbos

Helle Kirstein Erichsen

The Research and Scientific Development team at Gubra is dedicated to advancing the company's proprietary early target and drug discovery programs and supporting preclinical contract research services. Specializing in metabolic diseases such as obesity, diabetes, and NASH, the team leverages expertise in peptide chemistry, pharmacology, imaging, and bioinformatics. They conduct in-depth studies using advanced techniques like NGS and AI technology to drive scientific innovation and deliver high-quality research outcomes for global pharmaceutical, biotech partners, and academic collaborators.

Research and Scientific Development

Leadership Team

Research & Development

Research and Scientific Development

About

Team members

Other teams at Gubra

Leadership Team

Research & Development